Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mpox Outbreaks Beyond Historically Endemic Regions: A Clinical Review of Vaccination Strategies and Public Health Challenges.

Dermatology (Basel, Switzerland)·2026
Same author

Geographic diversity in top dermatology journal editorial boards.

The British journal of dermatology·2026
Same author

A rare case of carcinoma erysipeloides/en cuirasse secondary to metastatic cutaneous apocrine adenocarcinoma.

JAAD case reports·2026
Same author

Diagnosis and management of acyclovir-resistant herpes simplex virus for the dermatologist.

Journal of the American Academy of Dermatology·2026
Same author

Oncolytic viruses in cutaneous oncology: Mechanisms, clinical applications, and future directions.

Advances in cancer research·2026
Same author

Pancreatic Panniculitis in a Patient With Lung Cancer.

JAMA dermatology·2026
Same journal

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

American journal of clinical dermatology·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
Same journal

What's New in Photoprotection?

American journal of clinical dermatology·2026
Same journal

Primary Cutaneous Cryptococcosis in Immunocompetent Patients: Recognition and Management.

American journal of clinical dermatology·2026
Same journal

Practical Therapeutic Strategies for Acne-Induced Hyperpigmentation Across all Skin Types.

American journal of clinical dermatology·2026
See all related articles
  1. Home
  3. Dermatologic Adverse Events Associated With T-cell Engager Therapy.
  1. Home
  3. Dermatologic Adverse Events Associated With T-cell Engager Therapy.

Related Experiment Video

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Dermatologic Adverse Events Associated with T-Cell Engager Therapy.

Mihir K Patil1,2,3, Brigette Wang1,2,4, Nicole R LeBoeuf1,5

  • 1Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Avenue, 1st Floor, Boston, MA, 02115, USA.

American Journal of Clinical Dermatology
|June 2, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

T-cell engager immunotherapies cause unique skin side effects. Recognizing these patterns is key for dermatologists to manage patient care effectively.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

  • Oncology
  • Immunotherapy
  • Dermatology

Background:

  • T-cell engager therapies are a rapidly expanding class of anticancer immunotherapy.
  • Distinct dermatologic adverse events are increasingly recognized across these agents.
  • Understanding these toxicities is crucial for clinical management.

Purpose of the Study:

  • To review the spectrum of dermatologic adverse events associated with T-cell engager therapies.
  • To highlight agent-specific and mechanistically linked cutaneous toxicities.
  • To inform dermatologists on managing these side effects.

Main Methods:

  • Review of emerging literature on T-cell engager therapies and their dermatologic toxicities.
  • Analysis of reported adverse events, focusing on specific agents like tebentafusp and talquetamab.
  • Categorization of toxicities based on agent targets and mechanisms.

    • Main Results:

    • Tebentafusp and talquetamab show high rates of dermatologic toxicity due to on-target, off-tumor effects.
    • Tebentafusp commonly causes diffuse, photodistributed erythematous eruptions.
    • Talquetamab presents with unique cutaneous, nail, and oral toxicities linked to its target.
    • Other agents like blinatumomab and CD20-directed therapies are associated with various rashes.
    • Most skin toxicities are manageable with standard dermatologic treatments.

    Conclusions:

    • T-cell engager therapies present a range of predictable dermatologic adverse events.
    • Agent-specific patterns of skin toxicity are linked to their mechanisms of action.
    • Dermatologists play a vital role in managing these side effects, ensuring treatment continuity.